Improving access to care and services
We collaborate with public and private sector organizations to expand access to care and services to improve global health.
Featured stories
-
-
Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children
Sub-Saharan African Ministries of Health Invited to Submit Expression of Interest to Participate in New EffortDonation Program to be Part of Broader Initiative to Raise Awareness and Action
-
-
Johnson & Johnson secures a top spot on the 2016 Access to Medicine Index
The index looks at companies that do the best job of providing access to medications in developing countries. Johnson & Johnson ranked #2—and here’s why.
More from Johnson & Johnson
-
Patients share what it’s like to have wAIHA, a disease that causes the immune system to destroy red blood cells
Warm autoimmune hemolytic anemia is a rare, life-threatening disease that causes intense fatigue. Johnson & Johnson has a new therapy that targets the underlying drivers of the disease. Here, two patients—and Johnson & Johnson employees—share their journey, from symptoms and diagnosis to managing work and personal life. -
5 things we now know about prostate cancer
This disease is highly treatable if caught early—but in its earliest stages, prostate cancer often has no symptoms, allowing it to develop without detection. Learn more about this common cancer and how Johnson & Johnson is innovating across both early-stage and advanced disease. -
Striving for a cure for multiple myeloma: What HCPs need to know
Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.
